Medical - Devices
Compare Stocks
5 / 10Stock Comparison
DHAI vs MBOT vs ISRG vs NVCR vs SYK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Devices
DHAI vs MBOT vs ISRG vs NVCR vs SYK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $51K | $143M | $161.07B | $1.92B | $112.69B |
| Revenue (TTM) | $63M | $0.00 | $10.58B | $674M | $25.12B |
| Net Income (TTM) | $-9M | $-13M | $2.98B | $-173M | $3.25B |
| Gross Margin | 51.0% | — | 66.3% | 75.2% | 63.5% |
| Operating Margin | -7.7% | — | 30.5% | -27.2% | 22.4% |
| Forward P/E | — | — | 43.3x | — | 19.1x |
| Total Debt | $12M | $111K | $303M | $290M | $14.86B |
| Cash & Equiv. | $2M | $3M | $3.37B | $103M | $4.01B |
DHAI vs MBOT vs ISRG vs NVCR vs SYK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 24 | Apr 26 | Return |
|---|---|---|---|
| DIH Holding US, Inc. (DHAI) | 100 | 0.2 | -99.8% |
| Microbot Medical In… (MBOT) | 100 | 156.3 | +56.3% |
| Intuitive Surgical,… (ISRG) | 100 | 146.9 | +46.9% |
| NovoCure Limited (NVCR) | 100 | 84.5 | -15.5% |
| Stryker Corporation (SYK) | 100 | 100.7 | +0.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DHAI vs MBOT vs ISRG vs NVCR vs SYK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DHAI lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, MBOT doesn't own a clear edge in any measured category.
ISRG carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 5.5% 10Y total return vs SYK's 187.1%
- Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
- Beta 1.02, current ratio 4.87x
NVCR ranks third and is worth considering specifically for momentum.
- +1.1% vs DHAI's -99.3%
SYK is the #2 pick in this set and the best alternative if income & stability and valuation efficiency is your priority.
- Dividend streak 34 yrs, beta 0.55, yield 1.1%
- PEG 1.28 vs ISRG's 1.99
- Better valuation composite
- Beta 0.55 vs NVCR's 2.20, lower leverage
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs MBOT's -17.1% | |
| Value | Better valuation composite | |
| Quality / Margins | 28.2% margin vs NVCR's -25.7% | |
| Stability / Safety | Beta 0.55 vs NVCR's 2.20, lower leverage | |
| Dividends | 1.1% yield; 34-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +1.1% vs DHAI's -99.3% | |
| Efficiency (ROA) | 14.8% ROA vs MBOT's -34.4%, ROIC 15.0% vs -6.2% |
DHAI vs MBOT vs ISRG vs NVCR vs SYK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
DHAI vs MBOT vs ISRG vs NVCR vs SYK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 2 of 6 categories
SYK leads 2 • DHAI leads 0 • MBOT leads 0 • NVCR leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SYK and MBOT operate at a comparable scale, with $25.1B and $0 in trailing revenue. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $63M | $0 | $10.6B | $674M | $25.1B |
| EBITDAEarnings before interest/tax | -$4M | -$14M | $3.8B | -$165M | $6.3B |
| Net IncomeAfter-tax profit | -$9M | -$13M | $3.0B | -$173M | $3.2B |
| Free Cash FlowCash after capex | -$5M | -$11M | $2.8B | -$48M | $4.3B |
| Gross MarginGross profit ÷ Revenue | +51.0% | — | +66.3% | +75.2% | +63.5% |
| Operating MarginEBIT ÷ Revenue | -7.7% | — | +30.5% | -27.2% | +22.4% |
| Net MarginNet income ÷ Revenue | -13.8% | — | +28.2% | -25.7% | +12.9% |
| FCF MarginFCF ÷ Revenue | -7.4% | — | +26.8% | -7.1% | +17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -27.1% | — | +23.0% | +12.3% | +11.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +22.6% | +62.8% | +18.8% | -100.0% | +56.0% |
Valuation Metrics
SYK leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 35.0x trailing earnings, SYK trades at a 39% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.36x vs ISRG's 2.65x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $50,711 | $143M | $161.1B | $1.9B | $112.7B |
| Enterprise ValueMkt cap + debt − cash | $10M | $140M | $158.0B | $2.1B | $123.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -2.92x | 57.62x | -13.80x | 35.03x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 43.35x | — | 19.06x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.65x | — | 2.36x |
| EV / EBITDAEnterprise value multiple | — | — | 43.62x | — | 20.31x |
| Price / SalesMarket cap ÷ Revenue | 0.00x | — | 16.00x | 2.92x | 4.49x |
| Price / BookPrice ÷ Book value/share | — | 9.44x | 9.17x | 5.51x | 5.02x |
| Price / FCFMarket cap ÷ FCF | — | — | 64.67x | — | 26.31x |
Profitability & Efficiency
ISRG leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-51 for NVCR. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs MBOT's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -37.1% | +16.9% | -50.8% | +15.0% |
| ROA (TTM)Return on assets | -32.4% | -34.4% | +14.8% | -16.5% | +6.9% |
| ROICReturn on invested capital | — | -6.2% | +15.0% | -16.4% | +11.4% |
| ROCEReturn on capital employed | — | -2.9% | +16.5% | -28.9% | +13.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 | 6 | 5 | 6 |
| Debt / EquityFinancial leverage | — | 0.03x | 0.02x | 0.85x | 0.66x |
| Net DebtTotal debt minus cash | $10M | -$3M | -$3.1B | $187M | $10.8B |
| Cash & Equiv.Liquid assets | $2M | $3M | $3.4B | $103M | $4.0B |
| Total DebtShort + long-term debt | $12M | $111,000 | $303M | $290M | $14.9B |
| Interest CoverageEBIT ÷ Interest expense | -21.37x | — | — | -96.80x | 6.72x |
Total Returns (Dividends Reinvested)
Evenly matched — MBOT and ISRG each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $9 for DHAI. Over the past 12 months, NVCR leads with a +1.1% total return vs DHAI's -99.3%. The 3-year compound annual growth rate (CAGR) favors MBOT at 22.8% vs DHAI's -90.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +837.5% | +0.9% | -19.3% | +28.3% | -15.2% |
| 1-Year ReturnPast 12 months | -99.3% | -15.1% | -15.4% | +1.1% | -22.5% |
| 3-Year ReturnCumulative with dividends | -99.9% | +85.2% | +49.6% | -75.7% | +5.5% |
| 5-Year ReturnCumulative with dividends | -99.9% | -69.7% | +58.7% | -91.3% | +21.5% |
| 10-Year ReturnCumulative with dividends | -99.9% | -99.4% | +554.2% | +30.3% | +187.1% |
| CAGR (3Y)Annualised 3-year return | -90.3% | +22.8% | +14.4% | -37.6% | +1.8% |
Risk & Volatility
Evenly matched — DHAI and NVCR each lead in 1 of 2 comparable metrics.
Risk & Volatility
DHAI is the less volatile stock with a -1.13 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs DHAI's 0.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -1.21x | 1.90x | 1.00x | 2.15x | 0.52x |
| 52-Week HighHighest price in past year | $8.99 | $4.67 | $603.88 | $20.06 | $404.87 |
| 52-Week LowLowest price in past year | $0.00 | $1.60 | $427.84 | $9.82 | $289.91 |
| % of 52W HighCurrent price vs 52-week peak | +0.3% | +45.6% | +75.1% | +83.9% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 38.1 | 46.3 | 42.4 | 69.8 | 24.3 |
| Avg Volume (50D)Average daily shares traded | 2K | 1.5M | 1.8M | 1.5M | 2.1M |
Analyst Outlook
SYK leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: MBOT as "Buy", ISRG as "Buy", NVCR as "Buy", SYK as "Buy". Consensus price targets imply 158.2% upside for MBOT (target: $6) vs 32.4% for SYK (target: $390). SYK is the only dividend payer here at 1.14% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $5.50 | $622.60 | $33.50 | $389.62 |
| # AnalystsCovering analysts | — | 3 | 55 | 15 | 50 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +1.1% |
| Dividend StreakConsecutive years of raises | — | 0 | — | — | 34 |
| Dividend / ShareAnnual DPS | — | — | — | — | $3.36 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.4% | 0.0% | 0.0% |
ISRG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SYK leads in 2 (Valuation Metrics, Analyst Outlook). 2 tied.
DHAI vs MBOT vs ISRG vs NVCR vs SYK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is DHAI or MBOT or ISRG or NVCR or SYK a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -2. 5% for DIH Holding US, Inc. (DHAI). Stryker Corporation (SYK) offers the better valuation at 35. 0x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Microbot Medical Inc. (MBOT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DHAI or MBOT or ISRG or NVCR or SYK?
On trailing P/E, Stryker Corporation (SYK) is the cheapest at 35.
0x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Stryker Corporation is actually cheaper at 19. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 28x versus Intuitive Surgical, Inc. 's 1. 99x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — DHAI or MBOT or ISRG or NVCR or SYK?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +58. 7%, compared to -99. 9% for DIH Holding US, Inc. (DHAI). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus DHAI's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DHAI or MBOT or ISRG or NVCR or SYK?
By beta (market sensitivity over 5 years), DIH Holding US, Inc.
(DHAI) is the lower-risk stock at -1. 21β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately -278% more volatile than DHAI relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — DHAI or MBOT or ISRG or NVCR or SYK?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus -2. 5% for DIH Holding US, Inc. (DHAI). On earnings-per-share growth, the picture is similar: Microbot Medical Inc. grew EPS 30. 5% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DHAI or MBOT or ISRG or NVCR or SYK?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DHAI or MBOT or ISRG or NVCR or SYK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 28x versus Intuitive Surgical, Inc. 's 1. 99x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Stryker Corporation (SYK) trades at 19. 1x forward P/E versus 43. 3x for Intuitive Surgical, Inc. — 24. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MBOT: 158. 2% to $5. 50.
08Which pays a better dividend — DHAI or MBOT or ISRG or NVCR or SYK?
In this comparison, SYK (1.
1% yield) pays a dividend. DHAI, MBOT, ISRG, NVCR do not pay a meaningful dividend and should not be held primarily for income.
09Is DHAI or MBOT or ISRG or NVCR or SYK better for a retirement portfolio?
For long-horizon retirement investors, DIH Holding US, Inc.
(DHAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -1. 21)). Microbot Medical Inc. (MBOT) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DHAI: -99. 9%, MBOT: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DHAI and MBOT and ISRG and NVCR and SYK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: DHAI is a small-cap quality compounder stock; MBOT is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock; SYK is a mid-cap quality compounder stock. SYK pays a dividend while DHAI, MBOT, ISRG, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.